Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Revenue of Ikena Oncology, Inc. (IKNA)
Revenue in 2023 (TTM): $9.16 M
According to Ikena Oncology, Inc.'s latest financial reports the company's current revenue (TTM) is $9.16 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Ikena Oncology, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $9.16 M | $-50,492,000 | $-74,397,000 | $-68,328,000 | $-68,166,000 |
| 2022 | $15.62 M | $13.58 M | $-70,153,000 | $-68,765,000 | $-66,626,000 |
| 2021 | $30.99 M | $-16,123,000 | $-33,594,000 | $-34,115,000 | $-34,115,000 |
| 2020 | $9.19 M | $-35,653,000 | $-44,219,000 | $-44,256,000 | $-44,256,000 |
| 2019 | $13.75 M | $-11,185,000 | $-18,249,000 | $-16,817,000 | $-16,817,000 |
| 2018 | $990 K | $-37,996,000 | $-40,443,000 | $-40,865,000 | $-40,865,000 |